Amerisourcebergen Corporation

Spending by Year

Lobbying Firms

What They Lobby For

• - Issues related to LIFO (last in, first out)
• - Medicare prompt pay discount exclusion, including legislation to ensure appropriate reimbursement for drugs and biologics under Medicare Part B by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's Average Sales Price (ASP) (H.R. 1920); ASP, generally (in the context of Deficit Reduction) - Legislation to exclude cancer drugs from sequestration cuts; Cancer Care Payment Reform Act (H.R. 1834/S. 463)
• - Legislation to prevent and reduce prescription drug abuse; Ensuring Patient Access and Effective Drug Enforcement Act (Pub.L. 114-145) - Legislation to prohibit prescription drug plan sponsors and MA-PD organizations under Medicare from retroactively reducing payment on clean claims submitted by pharmacies - Issues related to pharmaceutical compounding and implementation of the Drug Quality Security Act (Pub.L. 113-54) - Issues related to drug pricing, including the Improving Access to Affordable Prescription Drug Act (H.R. 1776/S. 771) - Issues related to the importation of prescription medicines, including the Affordable and Safe Prescription Drug Importation Act (H.R. 1245/S. 469); and the Improving Access to Affordable Prescription Drugs Act (H.R. 1776/S. 771)
• Medicare prompt pay discount exclusion, including legislation to ensure appropriate reimbursement for drugs and biologics under Medicare Part B by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's Average Sales Price (ASP) (H.R. 1920); ASP, generally Legislation to exclude cancer drugs from sequestration cuts
• Legislation to prevent and reduce prescription drug abuse; Ensuring Patient Access and Effective Drug Enforcement Act (Pub.L. 114-145) Legislation to prohibit prescription drug plan sponsors and MA-PD organizations under Medicare from retroactively reducing payment on clean claims submitted by pharmacies Issues related to pharmaceutical compounding and implementation of the Drug Quality Security Act (Pub.L. 113-54). FDA implementation of Section 503B of the FFDCA HHS Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs. Issues related to drug pricing, including the Improving Access to Affordable Prescription Drug Act (H.R. 1776/S. 771) Issues related to the importation of prescription medicines, including the Affordable and Safe Prescription Drug Importation Act (H.R. 1245/S. 469); and the Improving Access to Affordable Prescription Drugs Act (H.R. 1776/S. 771)
• Medicare prompt pay discount exclusion, including legislation to ensure appropriate reimbursement for drugs and biologics under Medicare Part B by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's Average Sales Price (ASP) (H.R. 1920); ASP, generally
• Medicare prompt pay discount exclusion, including legislation to ensure appropriate reimbursement for drugs and biologics under Medicare Part B by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's Average Sales Price (ASP) (H.R. 1920); ASP, generally Medicare Part D, including removal of safe harbor protection for drug rebates Medicare Part B, including proposals to create an international pricing index, establish a competitive acquisition program
• Legislation to prevent and reduce prescription drug abuse Legislation to prohibit prescription drug plan sponsors and MA-PD organizations under Medicare from retroactively reducing payment on clean claims submitted by pharmacies Issues related to pharmaceutical compounding and implementation of the Drug Quality Security Act (Pub.L. 113-54). FDA implementation of Section 503B of the FFDCA Issues related to the HHS Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs Issues related to drug pricing, generally Issues related to the importation of prescription medicines
• Medicare prompt pay discount exclusion, including legislation to ensure appropriate reimbursement for drugs and biologics under Medicare Part B by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's Average Sales Price (ASP). ASP, generally Issues related to the HHS Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs Medicare Part D, including removal of safe harbor protection for drug rebates Medicare Part B, including proposals to create an international pricing index and establish a competitive acquisition program
• S. 988 and H.R. 803; legislation to prohibit prescription drug plan sponsors and MAPD organizations under Medicare program from retroactively reducing payment on clean claims submitted by pharmacies. Issues related to pharmaceutical compounding and implementation of the Drug Quality Security Act (Pub.L. 113-54). FDA implementation of Section 503B of the FFDCA. Issues related to drug pricing and transparency, generally. Issues related to the importation of prescription medicines

Related Investigations

Explore More